The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort study
Authors:
- Sophie MartinSMSophie Martin
- Aurélie FritschAFAurélie Fritsch
- Christelle JouannaudCJChristelle Jouannaud
- Jérôme Martin-BabauJMJérôme Martin-Babau
- Bertrand MennecierBMBertrand Mennecier
- Florian SlimanoFSFlorian Slimano
- Alizée BordeauABAlizée Bordeau
- Laure Guéroult-AccolasLGLaure Guéroult-Accolas
- Bernard DelcourBDBernard Delcour
- Eric RaymondEREric Raymond
- Sophie RenetSRSophie Renet
- Cécile Sonntag-MottierCSCécile Sonntag-Mottier
- 15 January 2026
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 98
Abstract
Purpose Remote patient monitoring of symptoms is now recommended by International oncology guidelines. In France, knowledge of real-world outcomes using telemonitoring is limited. This real-world French study aimed to evaluate the effectiveness of a telemonitoring solution in patients receiving cancer care. Methods The Continuum + Connect solution enables the sending of questionnaires and messages to the oncology team. All patients using the solution between October 1, 2021, and June 30, 2023, were eligible. Patients could respond either by themselves (Self-evaluated [SE]) or with the assistance of homecare nurses (Professionally-assisted [PA]). This retrospective real-world observational cohort study included all patients who started using the Continuum + solution during the study period. Descriptive analyses were performed. Study endpoints included conditions of use, quality of life, medication adherence, and safety outcomes. Results Overall, 1,294 patients (SE:19% PA 81%) were included. The mean age was 68.6 years (PA 71.0) and 66.9% were women (PA 63.3%). Most patients (77.3%) received treatment at home, mainly for breast, lung, or renal cancer. Compliance with telemonitoring was satisfactory. No deterioration in quality of life or treatment adherence was observed during the first 3 months of treatment. Overall, 25.3% of patients reported grade 3–4 adverse events, of which only 2.5% represented a deterioration from grade 1–2 to grade 3–4. Conclusion The Continuum + Connect is feasible and effective for the routine monitoring of symptoms, regardless of the patient’s profile. These real-world results provide useful insights and support further research.Keywords
This publication has 21 references indexed in Scilit:
- Cancer Prevention EuropeMolecular Oncology, 2019
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- Trends in Seniors’ Use of Digital Health Technology in the United States, 2011-2014JAMA, 2016
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialJournal of Clinical Oncology, 2016
- Cancer Survivorship Issues: Life After Treatment and Implications for an Aging PopulationJournal of Clinical Oncology, 2014
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S.Supportive Care in Cancer, 2008
- [Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic].2001